Sign inJoin waitlistJoin the waitlist

Philip Kuriakose

Chief, Section of Hematology · Henry Ford Health

Credentials: · · · · ·

History

Section of Hematology · Henry Ford Health
Present
Hemophilia & Thrombosis Treatment Center · Henry Ford Health
Present

Mayo Clinic
1999–2002
Christian Medical College/Hospital
1987–1990
Christian Medical College Vellore

Research

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia
Journal of Clinical Oncology · 2013 · 149 citations
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes
Cancer · 2017 · 90 citations
Risk of deep venous thrombosis associated with chest versus arm central venous subcutaneous port catheters: a 5-year single-institution retrospective study
Journal of Vascular and Interventional Radiology · 2002 · First of 3 authors · Corresponding · 73 citations

Vrushali Dabak
9 papers · 4 as a fellow
JM
Javier Munoz
6 papers · 6 as a fellow
AH
Amr Hanbali
5 papers
CK
Christine Kempton
5 papers
WQ
Waqas Qureshi
5 papers · 5 as a fellow
AS
Amy Shapiro
4 papers
MR
Margaret Ragni
4 papers
KM
Koichi Maeda
3 papers
Marwan Abouljoud
3 papers
MR
Michael Recht
3 papers · 1 as a resident
Miguel Escobar
3 papers
Suchitra Acharya
3 papers

Clinical trials

Natural History Study of Factor IX Treatment and Complications
Principal investigator · Unknown
Skane University Hospital
2015–2021
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Site PI · Recruiting · Phase 3
Takeda
2026–2028
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2024–2030
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2030